Industry’s Fastest Growing Shoulder System Marks 10 Years of Improving Patient Outcomes
18 November 2014 - 12:08AM
Business Wire
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone
and joint restoration products for hip, knee, shoulder, spine and
biologic materials, this week recognizes the 10th anniversary of
its unique Equinoxe® Shoulder System.
The Equinoxe system’s platform design enables surgeons to
convert from either a primary shoulder or fracture hemiarthroplasty
to a reverse shoulder without stem removal. The primary system was
launched in 2004, the reverse system was introduced in 2007 and the
system now includes several proprietary glenoid options. The
product line’s success continues to exceed company expectations,
currently leading the industry as the fastest growing shoulder.
Exactech has sold approximately 60,000 Equinoxe shoulders since the
first surgeries on November 16, 2004.
“The Equinoxe system has been successful because a diverse group
of surgeons and engineers collaborated to produce a unique product
that solves clinical challenges,” said Darin Johnson, Vice
President, Extremities and Hips at Exactech. “It is built on a
biomechanically sound, anatomic design philosophy that provides
intraoperative flexibility and unrivaled glenoid solutions for
surgeons – all supported by dozens of publications and
presentations at scientific meetings.”
Joseph Zuckerman, MD, one of the original design team members,
stated, “We began the development of the Equinoxe system with the
goal of designing an arthroplasty system that would enable surgeons
to address the entire spectrum of complex clinical problems. I am
very proud that Equinoxe has led the industry as the first shoulder
design that allowed the surgeon to replicate a patient’s unique
anatomy by independently adjusting parameters in situ. It has been
a gratifying project because we have delivered on our original
goal.”
“We started Exactech 30 years ago in order to solve clinical
challenges with designs that improve patient outcomes,” said
William Petty, MD, Executive Chairman of Exactech and one of the
company’s founders. “I am especially proud that one of our best
examples of this, the Equinoxe system, has now helped thousands of
patients get back to the activities of daily life.”
Orthopaedic surgeons who want to learn more about the Equinoxe
system and the latest techniques in shoulder replacement can take
advantage of Exactech’s personalized medical education programs.
Surgeons can design the workshop that best meets their individual
preferences, including live surgery observation, hands-on courses,
hospital in-service programs or in-depth technical review with
Exactech staff at the corporate headquarters.
About Exactech
Based in Gainesville, Fla., Exactech develops and markets
orthopaedic implant devices, related surgical instruments and
biologic materials and services to hospitals and physicians. The
company manufactures many of its orthopaedic devices at its
Gainesville facility. Exactech’s orthopaedic products are used in
the restoration of bones and joints that have deteriorated as a
result of injury or diseases such as arthritis. Exactech markets
its products in the United States, in addition to more than 30
markets in Europe, Latin America, Asia and the Pacific. Additional
information about Exactech, Inc. can be found at
http://www.exac.com. Copies of Exactech’s press releases, SEC
filings, current price quotes and other valuable information for
investors may be found at http://www.exac.com and
http://www.hawkassociates.com.
An investment profile on Exactech may be found at
http://www.hawkassociates.com/profile/exac.cfm. To receive future
releases in e-mail alerts, sign up at
http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which represent
the company’s expectations or beliefs concerning future events of
the company’s financial performance. These forward-looking
statements are further qualified by important factors that could
cause actual results to differ materially from those in the
forward-looking statements. These factors include the effect of
competitive pricing, the company’s dependence on the ability of
third party manufacturers to produce components on a basis which is
cost-effective to the company, market acceptance of the company’s
products and the effects of government regulation. Results actually
achieved may differ materially from expected results included in
these statements.
Exactech, Inc.Investor contactsJody Phillips, 352-377-1140Chief
Financial OfficerorHawk AssociatesJulie Marshall or Frank Hawkins,
305-451-1888E-mail: exactech@hawkassociates.com
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Apr 2024 to May 2024
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From May 2023 to May 2024